Remove Blogging Remove Class Remove Invest Remove San Diego
article thumbnail

VelosBio Emerges with $58M in Funding to Steer Cancer Drugs to Clinic

Xconomy

VelosBio joined Johnson & Johnson’s JLABS @ San Diego incubator in January. The company is developing antibody drug conjugates, a class of cancer drug that links antibodies to potent cancer-fighting toxins. The new VelosBio cash, a Series A round of financing, was led by Arix Bioscience (LSE: ARIX ) and Sofinnova Ventures.

article thumbnail

Profitability Helps San Diego Lender Step Out from Industry Cloud

Xconomy

In contrast to some alternative lenders, the San Diego firm said it is growing fast and is consistently profitable. Another oft-mentioned concern about peer-to-peer lenders is that most members of the new class of lending companies have yet to prove their business model in the ultimate stress test —an economic downturn.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

With $20M, UCSD Spinout Jecure To Press New Attack On NASH

Xconomy

For these reasons, fatty liver disease is often called a “silent disease,” says Ariel Feldstein, a gastroenterologist at the University of California San Diego. Feldstein has been studying the liver for nearly 20 years, and his research now forms the basis of a newly launched company called Jecure Therapeutics.

UCSD 64
article thumbnail

Effector Raises $38.6M to Advance New Class of Anti-Cancer Drugs

Xconomy

San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 The Series C financing, led by Pfizer Venture Investments, brings total funding for Effector to about $150 million, CEO Steve Worland said late Monday. million in new venture capital funding.

Class 59
article thumbnail

Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)

Xconomy

In every new (drug) class there’s always been people. Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138
article thumbnail

California Accelerators Enroll Startups Targeting Cannabis Industry

Xconomy

On Monday, nine startups began a 16-week program at Canopy San Diego , a new accelerator program for seed-stage companies developing new technologies, products, and services to support the legal cannabis industry. percent.

article thumbnail

How Next-Gen Chipmakers Are Raising Money, Taking On Tech Giants

Xconomy

The advent of big fundraising rounds for startup chip innovators—a class shunned by most venture capital firms only a few years ago—seems to mark a turnaround in recent VC attitudes about semiconductor investments.